CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Pharmaceutical giants are pivoting toward direct-to-consumer sales and offering steep drug discounts in the United States after President Donald Trump called for lower prescription prices and reduced reliance on “middlemen” such as insurers and pharmacy benefit managers. The move comes ahead of the Trump administration’s planned TrumpRx.gov launch in early 2026 — a federal website that will feature reduced drug prices.
U.S. patients currently pay nearly three times more for medicines than those in other developed countries. Following Trump’s July letters to 17 major firms demanding price cuts, several have responded with new pricing and sales models.
AbbVie announced it will launch its ovarian cancer drug Elahere in the UK at the same U.S. price, aligning with Trump’s “most-favored-nation” pricing policy. AstraZeneca struck a deal with the administration to sell select drugs at steep discounts through Medicaid and TrumpRx.gov, with up to 80% price reductions on some medicines. Bristol-Myers Squibb will cut prices on its blood clot drug Eliquis and plaque psoriasis treatment Sotyktu.
Eli Lilly began shipping high-dose Zepbound directly to consumers, while Novo Nordisk partnered with telehealth providers like GoodRx, Hims & Hers, and Ro to offer Ozempic and Wegovy to cash-paying patients. Pfizer also agreed to lower Medicaid prices to match global rates and will invest $70 billion in U.S. R&D in return for tariff relief.
Sanofi introduced a $35 monthly insulin cap for all U.S. patients, and Roche is exploring direct sales to consumers. Women’s telehealth platform Wisp expanded to offer weight-loss drugs from Eli Lilly and Novo Nordisk with home delivery. Zealand Pharma is also weighing a similar model for its experimental obesity treatment.
Industry group PhRMA plans to launch AmericasMedicines.com in January, helping patients buy directly from manufacturers — signaling a major shift toward affordability and accessibility in the U.S. drug market.
